Lingyu Li

Dr. Lingyu Li


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Brain Research
Verified
Journal Article
Closed access
YLYixin Li
Yixin Li
JWJingxian Wu
Jingxian Wu
SYShanshan Yu
Shanshan Yu
JZJin Zhu
Jin Zhu
YZYang Zhou
Yang Zhou
YZYong Zhao
Yong Zhao

1 March 2022 in Brain Research Bulletin
Verified
Journal Article
Closed access
JLJing Luo
Jing Luo
JTJunyi Tan
Junyi Tan
NJNing Jiang
Ning Jiang
CYChanghong Yang
Changhong Yang
JCJialei Chen
Jialei Chen
YZYong Zhao
Yong Zhao

22 February 2024 in Signal, Image and Video Processing
Verified
Journal Article
Closed access
PDF file
JLJunjie Li
Junjie Li
KYKaixiang Yan
Kaixiang Yan
YYYu Yu
Yu Yu
XZXiaohui Zhan
Xiaohui Zhan
LLLingyu Li
Lingyu Li

1 January 2022 in BioMed Research International
Verified
Journal Article
Open access
PDF file
YGYunhao Gan
Yunhao Gan
FZFuxin Zhong
Fuxin Zhong
HWHao Wang
Hao Wang
LLLingyu Li
Lingyu Li
Background. Invasive breast carcinoma (BRCA) is a common type of breast cancer with a high clinical incidence. Thus, it is significant to find effective biomarkers for BRCA diagnosis and treatment. Although some members of armadillo (ARM) repeat family of proteins are confirmed to be biomarkers in cancers, the role of armadillo repeat‐containing 1 (ARMC1) in BRCA remains unknown. Methods. We firstly analyzed the ARMC1 expression in normal breast tissues and BRCA samples and its association with overall survival by the public database. Next, the χ2 test was used to evaluate the prognostic significance of ARMC1 expression in TCGA‐BRCA patient samples. The ARMC1 mutations in BRCA were explored in the cBioportal database. Besides, the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were used to explore the biological functions of ARMC1 in BRCA. Finally, immunohistochemistry and immunofluorescence staining were performed to validate the ARMC1 expression in BRCA. Results. ARMC1 expression in tumor samples was significantly higher than that in normal tissues, and higher expression of ARMC1 was related to lower survival. Moreover, the tumor stage and histology of BRCA patients were associated with ARMC1 expression. ARMC1 genetic mutations occurred in 32% of BRCA patients, and the amplification and high expression of ARMC1 accounted for most of them. Furthermore, functional enrichment analysis suggested that ARMC1 might be involved in the cell cycle in BRCA. Ultimately, increased ARMC1 expression was found in clinical breast carcinoma tissues by our confirmatory experiments. Conclusions. ARMC1 may play a significant role in BRCA and act as a biomarker, which provides valuable clues for the treatment and diagnosis of BRCA.

6 November 2025 in Biomedical Signal Processing and Control
Verified
Journal Article
Closed access
JLJunjie Li
Junjie Li
KYKaixiang Yan
Kaixiang Yan
YYYu Yu
Yu Yu
XZXiaohui Zhan
Xiaohui Zhan
LLLingyu Li
Lingyu Li

5 January 2022 in Research Square
Verified
Preprint
Open access
PDF file
YGYunhao Gan
Yunhao Gan
FZFuxin Zhong
Fuxin Zhong
LLLingyu Li
Lingyu Li
HWHao Wang
Hao Wang
Background: Invasive breast carcinoma (BRCA) is a common type of breast cancer with high incidence in clinics, so it is significant to find an effective biomarker for BRCA diagnosis and treatment. Although some Armadillo (Arm)-repeat proteins families are confirmed to be biomarkers in cancers, the role of Armadillo repeat-containing 1 (ARMC1) in BRCA remains unknown.Methods: We analyzed the ARMC1 expression in normal breast tissues and BRCA samples, and its association with overall survival by the public database. χ² test evaluated the risks associated with ARMC1 expression in TCGA-BRCA patient samples. The ARMC1 mutations in BRCA were explored in the cBioportal database. Besides, the GO and KEGG analysis was used to explore the potential signaling pathways of ARMC1 in BRCA. Lastly, Immunohistochemistry and immunohistochemistry were performed to validate the ARMC1 expression in BRCA.Results: ARMC1 level in tumor sample was significantly higher than that in normal tissue, and it was also related to lower survival. The factors in clinical patients such as tumor stage and grade and histology were associated with ARMC1 expression. There were 32% of ARMC1 genetic mutations in BRCA, and the amplification and high expression made up the majority of them. Also, ARMC1 might regulate BRCA by involving in the cell cycle. Increased ARMC1 expression was found in clinical breast carcinoma tissues by our confirmatory experiments.Conclusions: All the results revealed that ARMC1 may play a significant role in BRCA as a biomarker, it provides valuable clues for the treatment and diagnosis of invasive breast cancer.